Genesis Molecular AI
South San Francisco
About Genesis Molecular AI
Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI technologies. The company employs a combination of innovative deep neural networks, biophysical simulation techniques, and highly scalable computing infrastructure. This amalgamation of technologies is geared towards achieving remarkable results in molecular generation and property prediction, particularly in the field of drug discovery and molecular design. Established in 2019 and headquartered in South San Francisco, California, Genesis Therapeutics focuses on leveraging innovative AI methodologies to enhance the efficiency and accuracy of molecular research. The company's approach holds promise in revolutionizing how molecules are generated and analyzed, potentially leading to advancements in drug development and related fields.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $256.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2023)
- Website: genesis.ml
- Phone: +1(208) 991-4716
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/genesis-molecular-ai-106274 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.